“…Recent studies have assessed select immune markers, primarily in experimental systems. In animal models, HDM showed early Th2/Th22 skewing and upregulation of S100A8/9/12 at 6 hours post‐application, with parallel barrier changes (epidermal hyperplasia, decreased differentiation, increased TEWL) . In ex vivo cultures, HDM induced both Th2 (IL‐4, CCL17, TSLP) and Th17/Th22 markers, while in human keratinocytes co‐treated with IL‐17A, HDM showed robust increases in S100A8/9 expression .…”